SF2645

Purpose of the Bill

This bill seeks to amend Minnesota statutes concerning the operations and responsibilities of the Formulary Committee, which advises on drug formularies and prior authorizations. The bill aims to enhance transparency and public involvement in the committee’s decision-making processes, particularly concerning rare diseases.

Main Provisions

• Conflict of Interest Guidelines: Formulary Committee members with potential conflicts of interest are now allowed to participate in discussions but must publicly disclose conflicts. They cannot vote or communicate on matters where conflicts exist unless publicly disclosed 48 hours before relevant meetings.
• Public Comment Process: The commissioner of human services is tasked with developing a public comment process for the Formulary Committee’s recommendations. This includes informing the public about meetings and allowing public comments which must be published within 48 hours.
• Involvement of Rare Disease Council: The Formulary Committee is required to seek expertise from the Minnesota Rare Disease Advisory Council, especially concerning orphan drugs, which are drugs developed for rare diseases.
• Prior Authorization Changes: The bill dictates stricter regulations on when drugs, especially brand-name drugs with generic equivalents, can require prior authorization. It mandates a 15-day public comment period before implementing such authorizations.
• Preferred Drug List Modifications: Changes to the preferred drug list, like drug deletions or modifications, must now consider state public health policies and health disparities and require public hearings and disclosures.

Significant Changes to Existing Law

• The Formulary Committee is now required to meet at least three times a year, extending its expiration from 2027 to 2030.
• The act introduces a 30-day notice requirement before meetings, allowing experts and the public to contribute comments.
• The commissioner must publish the terms of contracts related to the preferred drug list and maintain a public archive of previous lists.
• Automatic prior authorizations for newly FDA-approved drugs are limited to 180 days unless further formal review occurs.

Relevant Terms

• Formulary Committee
• Conflict of Interest
• Public Comment Process
• Minnesota Rare Disease Advisory Council
• Prior Authorization
• Orphan Drugs
• Preferred Drug List
• Health Disparities